In keeping with this, recent studies in subcutaneous mouse tumour models have shown that CXCR3 is not required for tumour infiltration but is important for positioning T cells to receive anti-tumour activation signals from intratumoral DCs when paired with anti-PD-1 therapy (55). Here, PDCD1 is linked to neoplasm.